Global microbial gene editing services demand is anticipated to be valued at US$ 5.35 Billion in 2022, forecast to grow at a CAGR of 19% to be valued at US$ 30.5 Billion from 2022 to 2032.
Microbial gene editing is a technology that has the ability to change the DNA of organisms. Microbial gene editing is changing the ways of developing new medical treatments. From treating diseases such as sickle cell and HIV to custom pets and designer babies, microbial gene editing has great potential to affect all areas of life in the near future.
| Report Attribute | Details |
|---|---|
| Estimated Base Year Value (2021) | US$ 4.5 Billion |
| Expected Market Value (2022) | US$ 5.35 Billion |
| Anticipated Forecast Value (2032) | US$ 30.5 Billion |
| Projected Growth Rate (2022 to 2032) | 19% CAGR |
Development of new immunotherapies for diseases such as cancer as the rising prevalence of cancer which will significantly grow in the future will provide an opportunity for microbial gene editing. For instance, the first-ever human trials of CRISPR focused on treating various cancers in China and the first human trials for CRISPR tech in the USA set to focus on diseases such as sickle cell.
Progress in the availability of computational tools and wet-lab genome editing (GE) technologies has greatly expanded the capability for the complex requirements of a system-level investigation of microbes.
Microbial gene editing tools such as targeting, zinc finger nucleases (ZFNs), meganucleases (MNs), (CRISPR)-associated nuclease Cas9 and transcription activator-like effector nucleases (TALENs), and, creates huge opportunity for the gene editing in the forecast period. All these tools can achieve accurate and precise genetic modifications by inducing targeted DNA double-strand breaks.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Recent research and development in genome editing technologies hold promise in the forecast period for the development of innovative therapies. The use of genome tools has the potential to affect various therapeutic areas and hundreds of diseases, common and rare diseases which will significantly boost the market.
Over the years, Increased attention is given to the development of new antimicrobials which fight against antibiotic-resistant bacteria. For instance, Companies such as Nemesis Bioscience and Eligo Bioscience are developing antimicrobial technology and treatments with the help of CRISPR technology. Increasing government funding and the development of fast and easy methods with high efficiency spur the microbial gene editing services market in the forecast period.
Other factors like rising acceptance and increasing medical research and development for gene editing, growth of established and new gene editing tools, and rising clinical trials for diseases as diverse as muscular dystrophy, cancer, and sickle cell anemia will further drive the microbial gene editing services market. In addition to these factors, an increasing number of skilled laborers will create opportunities for the development of new tools in the future which will bring significant growth in the revenue of the microbial gene editing services market in the forecast period.
The challenges associated with the growth of the global microbial gene editing services market are variations in regulatory standards for different regions or countries. Moreover, certain limitations to the available tool and high costs associated with the editing systems might restrain the growth of the microbial gene editing services market.
Principal Consultant
According to Future Market Insights, the North American market for Microbial Gene Editing Services holds the largest revenue share, due to increasing research and development and rising government funding for microbial gene editing research.
For instance, in 2018, The USA National Institutes of Health (NIH) announced to grant US$190 million for genome editing research. The launch of genome editing programs by NIH such as Somatic Cell Genome Editing programs which aims to develop tools for safe and effective genome editing in humans spur the market of North America in the forecast period.
As per the FMI analysis, Europe accounts for the second largest revenue share in the global microbial gene editing services market, owing to the increasing prevalence of diseases such as HIV and Cancer and the development of new innovative technology and new drugs along with the increasing number of skilled laborers. Moreover, rapid growth is expected in the microbial gene editing services market, due to advances in technology and the establishment of scientific research groups and laboratories.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Asia Pacific is expected to witness rapid growth in the microbial gene editing services market, due to increasing awareness of gene editing services in developing countries such as India and improving healthcare infrastructure. China is expected to register significant growth in the microbial gene editing services market, due to favorable regulations and advancements in biotechnology.
Some of the key participants present in the global microbial gene editing services market include Creative Biogene, GeneCopoeia, Inc., ProteoGenix, Thermo Fisher Scientific Inc., Vigene Biosciences Inc, Biotools Co.Ltd, Cellecta, In, NemaMetrix Inc, GenScript Biotech Corp, OriGene Technologies, Inc, Synbio Technologies LLC, ABM Inc, and Rockland Immunochemicals Inc., among others. Attributed to the presence of such a high number of participants, the market is highly competitive.
| Report Attribute | Details |
|---|---|
| Market Value in 2022 | US$ 5.35 Billion |
| Market Value in 2032 | US$ 30.5 Billion |
| Growth Rate | CAGR of 19% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2017 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
FMI projects the global microbial gene editing services market to expand at a 19% value CAGR by 2032
North America is expected to be the most opportunistic microbial gene editing services market.
Creative Biogene, GeneCopoeia, Inc., and ProteoGenix, are some prominent microbial gene editing services manufacturers.
1. Executive Summary | Microbial Gene Editing Services Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. Value Chain Analysis
3.5.1. Profit Margin Analysis
3.5.2. Service Providers
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021
4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Tools
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Tools, 2017 to 2021
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Tools, 2022 to 2032
5.3.1. Meganucleases
5.3.2. Zinc Finger Nucleases
5.3.3. Transcription Activator-Like Effector Nucleases
5.3.4. CRISPR/Cas9
5.3.5. Targetrons
5.3.6. Peptide Nucleic Acids
5.3.7. Triplex-Forming Oligonucleotides
5.3.8. Structure-Guided Endonucleases
5.4. Y-o-Y Growth Trend Analysis By Tools, 2017 to 2021
5.5. Absolute $ Opportunity Analysis By Tools, 2022 to 2032
6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Application
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2017 to 2021
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2022 to 2032
6.3.1. Industrial Applications
6.3.2. Pharmaceutical Applications
6.3.3. Environmental Applications
6.3.4. Agricultural Applications
6.4. Y-o-Y Growth Trend Analysis By Application, 2017 to 2021
6.5. Absolute $ Opportunity Analysis By Application, 2022 to 2032
7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2017 to 2021
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2022 to 2032
7.3.1. Biotechnological Companies
7.3.2. Pharmaceutical Companies
7.3.3. Contract Research Organizations
7.3.4. Academic Research Institutes
7.4. Y-o-Y Growth Trend Analysis By End User, 2017 to 2021
7.5. Absolute $ Opportunity Analysis By End User, 2022 to 2032
8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. East Asia
8.3.5. South Asia & Pacific
8.3.6. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Tools
9.2.3. By Application
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Tools
9.3.3. By Application
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. Mexico
10.2.1.2. Brazil
10.2.1.3. Rest of Latin America
10.2.2. By Tools
10.2.3. By Application
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Tools
10.3.3. By Application
10.3.4. By End User
10.4. Key Takeaways
11. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. Italy
11.2.1.3. France
11.2.1.4. United Kingdom
11.2.1.5. Spain
11.2.1.6. BENELUX
11.2.1.7. Russia
11.2.1.8. Rest of Europe
11.2.2. By Tools
11.2.3. By Application
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Tools
11.3.3. By Application
11.3.4. By End User
11.4. Key Takeaways
12. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Tools
12.2.3. By Application
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Tools
12.3.3. By Application
12.3.4. By End User
12.4. Key Takeaways
13. South Asia & Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
13.2.1. By Country
13.2.1.1. India
13.2.1.2. ASEAN
13.2.1.3. Australia and New Zealand
13.2.1.4. Rest of South Asia & Pacific
13.2.2. By Tools
13.2.3. By Application
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Tools
13.3.3. By Application
13.3.4. By End User
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. Turkey
14.2.1.3. South Africa
14.2.1.4. Rest of Middle East and Africa
14.2.2. By Tools
14.2.3. By Application
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Tools
14.3.3. By Application
14.3.4. By End User
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Tools
15.1.2.2. By Application
15.1.2.3. By End User
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Tools
15.2.2.2. By Application
15.2.2.3. By End User
15.3. Mexico
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Tools
15.3.2.2. By Application
15.3.2.3. By End User
15.4. Brazil
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Tools
15.4.2.2. By Application
15.4.2.3. By End User
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Tools
15.5.2.2. By Application
15.5.2.3. By End User
15.6. Italy
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2021
15.6.2.1. By Tools
15.6.2.2. By Application
15.6.2.3. By End User
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2021
15.7.2.1. By Tools
15.7.2.2. By Application
15.7.2.3. By End User
15.8. United Kingdom
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2021
15.8.2.1. By Tools
15.8.2.2. By Application
15.8.2.3. By End User
15.9. Spain
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2021
15.9.2.1. By Tools
15.9.2.2. By Application
15.9.2.3. By End User
15.10. BENELUX
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2021
15.10.2.1. By Tools
15.10.2.2. By Application
15.10.2.3. By End User
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2021
15.11.2.1. By Tools
15.11.2.2. By Application
15.11.2.3. By End User
15.12. China
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2021
15.12.2.1. By Tools
15.12.2.2. By Application
15.12.2.3. By End User
15.13. Japan
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2021
15.13.2.1. By Tools
15.13.2.2. By Application
15.13.2.3. By End User
15.14. South Korea
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2021
15.14.2.1. By Tools
15.14.2.2. By Application
15.14.2.3. By End User
15.15. India
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2021
15.15.2.1. By Tools
15.15.2.2. By Application
15.15.2.3. By End User
15.16. ASIAN
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2021
15.16.2.1. By Tools
15.16.2.2. By Application
15.16.2.3. By End User
15.17. Australia and New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2021
15.17.2.1. By Tools
15.17.2.2. By Application
15.17.2.3. By End User
15.18. GCC Countries
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2021
15.18.2.1. By Tools
15.18.2.2. By Application
15.18.2.3. By End User
15.19. Turkey
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2021
15.19.2.1. By Tools
15.19.2.2. By Application
15.19.2.3. By End User
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2021
15.20.2.1. By Tools
15.20.2.2. By Application
15.20.2.3. By End User
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Tools
16.3.3. By Application
16.3.4. By End User
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Creative Biogene
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.1.5.2. Product Strategy
17.1.1.5.3. Channel Strategy
17.1.2. GeneCopoeia, Inc.
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.2.5.2. Product Strategy
17.1.2.5.3. Channel Strategy
17.1.3. ProteoGenix
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.3.5.2. Product Strategy
17.1.3.5.3. Channel Strategy
17.1.4. Thermo Fisher Scientific Inc.
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.4.5.2. Product Strategy
17.1.4.5.3. Channel Strategy
17.1.5. Charles River
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.5.5.2. Product Strategy
17.1.5.5.3. Channel Strategy
17.1.6. Biotools Co., Ltd
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.6.5.2. Product Strategy
17.1.6.5.3. Channel Strategy
17.1.7. Cellecta, Inc
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.7.5.2. Product Strategy
17.1.7.5.3. Channel Strategy
17.1.8. InVivo Biosystems
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.8.5.2. Product Strategy
17.1.8.5.3. Channel Strategy
17.1.9. GenScript Biotech Corp
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.9.5.2. Product Strategy
17.1.9.5.3. Channel Strategy
17.1.10. OriGene Technologies, Inc.
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.10.5.2. Product Strategy
17.1.10.5.3. Channel Strategy
17.1.11. Synbio Technologies LLC
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.11.5.2. Product Strategy
17.1.11.5.3. Channel Strategy
17.1.12. ABM Inc
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
17.1.12.5.2. Product Strategy
17.1.12.5.3. Channel Strategy
17.1.13. Rockland Immunochemicals Inc.
17.1.13.1. Overview
17.1.13.2. Product Portfolio
17.1.13.3. Profitability by Market Segments
17.1.13.4. Sales Footprint
17.1.13.5. Strategy Overview
17.1.13.5.1. Marketing Strategy
17.1.13.5.2. Product Strategy
17.1.13.5.3. Channel Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Microbial Gene Editing Services Market
